c4c (conect4children) was large collaborative public-private 7-year project. The project ended on 30th April 2025. The project resulted to establishment of new network structure, c4c-Stichting (c4c-S) providing high quality pediatric clinical trial services across all conditions and phases of the drug development process. The c4c-S office is located in Utrecht, Netherlands.

c4c project was about novel collaboration between 35 academic and 10 industry partners from 20 European countries, and more than 50 third parties and around 500 affiliated partners. The project total funding was 160 Million €. In Finland, HUS was one of the c4c-Beneficiaries, and other University Hospitals (4) in Finland were Third Parties to HUS for the P-o-V trial conduction.

c4c conducted several Proof-of-Viability (P-o-V) trials across Europe. Two academic trials were conducted in Finland; TREOCAPA: Paracetamol in Premature Babies: will assess the effectiveness of paracetamol on the closure of the ductus arteriosus and the increase in surviving without the severe morbidities of extreme premature infants and KD-CAAP: Kawasaki Disease Coronary Artery Aneurysm Prevention trial: will assess the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease. In addition, some industry sponsored trials were condusted during the project.

FINPEDMED was able to join c4c project due to the good credit of the previous operational history.